Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CD70 CAR-T for Relapsed/Refractory Glioma
NCT06828341Phase 1Recruiting
- Sponsor
- Jiangsu Longwei Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Allogeneic CD70-targeting CAR-T cells in glioma, sponsored by Jiangsu Longwei Pharmaceutical. Primary endpoint: Safety of allogeneic T cells at 2 years. Started Jun 2024; status: recruiting.
02
Drugs
Allogeneic CD70-targeting CAR-T cells
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06828341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828341.